CereGate closes oversubscribed Series C led by an unnamed US medtech company
Munich-based CereGate, which builds brain-computer interface software that runs on deep brain stimulation systems, closed a Series C round to fund clinical work on freezing of gait in Parkinson's disease. The amount was not disclosed.
CereGate, a Munich neurotechnology company founded in 2019, said on October 14 that it has closed an oversubscribed Series C round. The round was led by a US-based global medtech company that CereGate did not name. Existing investors took part again, and Budapest fund Impact Ventures joined as a new investor. The amount and valuation were not disclosed. CereGate’s software runs on Boston Scientific deep brain stimulation (DBS) systems and is in clinical studies, first for freezing of gait: sudden stops in walking that people with Parkinson’s disease can have even with optimized medication and standard DBS.
The money will go to clinical development. The company has not yet published efficacy results, and its therapy is not approved.
Learn more: Deep brain stimulation · CereGate